When Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Become Profitable?
When Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Become Profitable?
We feel now is a pretty good time to analyse BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) business as it appears the company may be on the cusp of a considerable accomplishment. BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The US$1.5b market-cap company posted a loss in its most recent financial year of US$227m and a latest trailing-twelve-month loss of US$124m shrinking the gap between loss and breakeven. As path to profitability is the topic on BioCryst Pharmaceuticals' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
我們認爲現在是分析biocryst製藥公司業務的一個相當好的時機,因爲該公司似乎即將取得重大成就。biocryst製藥公司是一家生物技術公司,開發口服小分子和蛋白治療藥物,用於治療罕見疾病。市值15億美元的公司在最近一個財政年度錄得虧損22700萬美元,並在最新的過去十二個月虧損12400萬美元,縮小虧損與盈利之間的差距。由於盈利路徑成爲biocryst製藥公司投資者關注的話題,我們決定評估市場情緒。我們爲該公司制定了一個簡要的行業分析師預期概況,包括公司的盈虧平衡年份和暗含增長率。
According to the 10 industry analysts covering BioCryst Pharmaceuticals, the consensus is that breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of US$48m in 2026. So, the company is predicted to breakeven approximately 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 73% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
根據對biocryst製藥公司進行覆蓋的10位行業分析師,他們一致認爲盈虧平衡即將到來。他們預計該公司將在2025年發佈最終虧損,然後在2026年實現4800萬美元的利潤。因此,預計公司將在大約2年後實現盈虧平衡。爲了達到這個盈虧平衡日期,我們計算了公司必須年度增長的速率。結果顯示預期的平均年增長率爲73%,這是非常樂觀的。如果這個增長率過於激進,公司可能會比分析師預測的時間盈利晚得多。
Given this is a high-level overview, we won't go into details of BioCryst Pharmaceuticals' upcoming projects, though, bear in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
考慮到這是一個高層概覽,我們不會詳細介紹biocryst製藥公司即將推出的項目,但請記住,一般而言,生物技術公司根據產品開發階段,現金流量會出現不規則週期。這意味着高增長率並不少見,尤其是如果公司目前正處於投資期。
Before we wrap up, there's one issue worth mentioning. BioCryst Pharmaceuticals currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag.
在我們結束之前,有一件值得一提的問題。biocryst製藥公司目前在資產負債表上出現負淨值。有時這可能是由於用於處理前幾年累積損失的會計方法而產生的,這些損失被視爲負債一直延續,直到將來抵消。往往,虧損只存在於紙面上,但有時可能是一個警示信號。
Next Steps:
下一步:
There are key fundamentals of BioCryst Pharmaceuticals which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at BioCryst Pharmaceuticals, take a look at BioCryst Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of key factors you should look at:
biocryst製藥公司有一些關鍵的基本因素沒有在本文中涵蓋,但我們必須再次強調,這只是一個基本概述。要更全面地了解biocryst製藥公司,請查看Simply Wall St上的biocryst製藥公司頁面。我們還編制了一份您應該關注的關鍵因素列表:
- Valuation: What is BioCryst Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether BioCryst Pharmaceuticals is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on BioCryst Pharmaceuticals's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:bioCryst製藥今天的價值是多少?未來的增長潛力是否已被市場考慮在內?我們免費研究報告中的內在價值信息圖可以幫助您了解BioCryst Pharmaceuticals目前是否被市場錯誤定價。
- 管理團隊:一個經驗豐富的管理團隊能增加我們對業務的信心 – 查看一下誰在biocryst製藥的董事會上以及CEO的背景。
- 其他高表現的股票:是否有其他表現更好的股票並具有經過驗證的歷史記錄?查看這裏的免費列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
譯文內容由第三人軟體翻譯。